Effect of Heart Failure on Dipeptidyl Peptidase <scp>IV</scp> Activity in Plasma of Dogs

Gomez, Nelson; Matheeussen, Veerle; Damoiseaux, Cécile; Tamborini, A.; Merveille, Anne-Christine; Jespers, Pascale; Michaux, Charles; Clercx, Cécile; Meester, Ingrid De; Entee, Kathleen Mc

doi:10.1111/j.1939-1676.2012.00942.x

Cited by 16 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DPP-4 removes the 2 amino-terminal amino acids from B-type natriuretic peptide (BNP) to produce BNP , which induces less natriuresis, diuresis, and vasodilation than BNP (1-32) [6]. Increased DPP-4 activity is associated with the pathophysiology of heart failure [7]. DPP-4 inhibitors have been thought to have cardio-protective effects owing to increases in the incretin hormones levels and BNP bioavailability in type 2 diabetes mellitus (T2DM) patients.…”

Section: Introductionmentioning

confidence: 99%

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

et al. 2015

View full text Add to dashboard Cite

Incretin hormones have been reported to have cytoprotective actions in addition to their glucose-lowering effects. We evaluated whether teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, affects left ventricular (LV) function in patients with type 2 diabetes mellitus (T2DM). Twenty-nine T2DM patients not receiving any incretin-based drugs were enrolled and prescribed with teneligliptin for 3 months. Compared to baseline levels, hemoglobin A1c levels decreased (7.6 ± 1.0 % to 6.9 ± 0.7 %, p < 0.01) and 1,5-anhydro-D-glucitol levels increased (9.6 ± 7.2 μg/mL to 13.5 ± 8.7 μg/mL, p < 0.01) after treatment. Clinical parameters, including body mass index and blood pressure, did not show any difference before and after treatment. Three months after treatment, there were improvements in LV systolic and diastolic function [LV ejection fraction, 62.0 ± 6.5 % to 64.5 ± 5.0 %, p = 0.01; peak early diastolic velocity/basal septal diastolic velocity (E/e') ratio, 13.3 ± 4.1 to 11.9 ± 3.3, p = 0.01]. Moreover, there was an improvement in endothelial function (reactive hyperemia peripheral arterial tonometry [RH-PAT] index; 1.58 ± 0.47 to 2.01 ± 0.72, p < 0.01). There was a significant negative correlation between changes in the E/e' ratio and RH-PAT values. Furthermore, circulating adiponectin levels increased (27.0 ± 38.5 pg/mL to 42.7 ± 33.2 pg/mL, p < 0.01) without changes in patient body weight. Teneligliptin treatment was associated with improvements in LV function and endothelial functions, and an increase in serum adiponectin levels. These results support the cardio-protective effects of teneligliptin in T2DM patients and increase in serum adiponectin levels.

show abstract

Section: Introductionmentioning

confidence: 99%

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Increased DPP4 activity is associated with pathophysiology of HF. DPP4 activity was measured in dogs with different degree of heart failure (HF): DPP4 activity increased linearly with body weight and was significantly higher in heart failure class 1 compared with healthy heart and heart failure class 3 demonstrating that DPP4 activity could be involved in early stages of heart failure [22]. …”

Section: In Vivo Evidencementioning

confidence: 99%

The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence

Pala

Rotella

2013

Journal of Diabetes Research

View full text Add to dashboard Cite

The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since these drugs not only improve glycemia with minimal risk of hypoglycemia, but also have other extraglycemic beneficial effects. These agents, which are effective in improving glucose control, could also have positive effects on the incidence of cardiovascular events. The aim of this review is to summarize the present literature about the role of dipeptidyl peptidase 4 (DPP4) in cardiovascular districts, not only strictly correlated to its effect on glucagon-like peptide-1 (GLP-1) circulating levels, but also to what is known about possible cardiovascular actions. Actually, DPP4 is known to be present in many cells and tissues and its effects go beyond purely metabolic aspects. Almost always the inhibition of DPP4 activity is associated with improved cardiovascular profile, but it has shown to possess antithrombotic properties and these different effects could be connected with a site and/or species specificity of DPP4. Certainly, DPP4 seems to exert many functions, both directly and indirectly, on cardiovascular districts, opening new possibilities of prevention and treatment of complications at this level, not only in patients affected by diabetes mellitus.

show abstract

“…Dipeptidyl peptidase‐4 (DPP‐4) rapidly inactivates incretins with a half‐life of a few minutes; therefore, DPP‐4 inhibitors or gliptin are currently used in the treatment of type 2 diabetes mellitus (T2DM). Recently, both experimental and clinical studies have suggested that DPP‐4 inhibitors can modulate cardiovascular function by ameliorating ischaemia‐reperfusion injury, reducing the atherosclerotic lesions and vascular inflammatory reaction, and protecting the heart from acute myocardial ischaemia . There are a number of underlying molecular mechanisms involved in angiopathy associated with diabetes that are recognized, where there is impaired nitric oxide (NO) bioavailability, to be the main cause of endothelial dysfunction.…”

Section: Introductionmentioning

confidence: 99%

Vascular effects of linagliptin in non‐obese diabetic mice are glucose‐independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin‐1 (CAV‐1) pathway

Vellecco

Mitidieri

Gargiulo

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Effect of Heart Failure on Dipeptidyl Peptidase IV Activity in Plasma of Dogs

Abstract: We did not find evidence that plasma DPP4 activity is responsible for the "BNP resistance" in overt congestive HF, but it may be implicated in early stages.

Cited by 16 publications

References 21 publications

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence

Vascular effects of linagliptin in non‐obese diabetic mice are glucose‐independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin‐1 (CAV‐1) pathway

Contact Info

Product

Resources

About